AI for accelerated antibody discovery Traditionally, mAbs are initially discovered (hit identification, or HI) through experimental techniques, like hybridoma screening or high throughput ...

the first DTI approved for HIT, is a bivalent thrombin inhibitor that is cleared by the kidneys. Neither argatroban nor lepirudin demonstrates cross-reactivity with heparin-induced antibodies, and ...

The global polyclonal antibody market is poised for significant expansion in the coming decade, driven by increasing ...

We have capabilities that equip us with the toolkit needed throughout the whole antibody development process, from hit identification to mid-scale production,” said Yamashita. “Our aim is to ...

The global Antibody Drug Conjugates market, valued at USD 10.28 billion in 2023, is expected to reach USD 29.10 billion by 2032, growing at a CAGR of 12.29% during the forecast period from 2024 to ...

With Libera Bio’s technology enabling the intracellular delivery of monoclonal antibodies, small molecules and more, drug developers can hit formerly inaccessible high-value targets and create ...

data on the use of bivalirudin in the treatment of HIT are limited. [31] Sarah A. Spinler, PharmD, FCCP, is an Associate Professor of Clinical Pharmacy, Department of Pharmacy Practice and ...